Pacira BioSciences, Inc. (FRA:82P)
Germany · Delayed Price · Currency is EUR 20.00
-0.20 (-0.99%)
Last updated: Dec 1, 2025, 3:56 PM CET
Pacira BioSciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 716.79 | 700.97 | 674.98 | 666.82 | 541.53 | 429.65 | Upgrade | |
Revenue Growth (YoY) | 3.14% | 3.85% | 1.22% | 23.14% | 26.04% | 2.05% | Upgrade |
Cost of Revenue | 246.14 | 252.01 | 260.93 | 284.09 | 195.8 | 176.75 | Upgrade |
Gross Profit | 470.65 | 448.96 | 414.05 | 382.73 | 345.73 | 252.9 | Upgrade |
Selling, General & Admin | 346.77 | 294.1 | 269.44 | 254.52 | 199.35 | 193.52 | Upgrade |
Amortization of Goodwill & Intangibles | 57.29 | 57.29 | 57.29 | 57.29 | 13.55 | 7.87 | Upgrade |
Other Operating Expenses | - | - | - | - | 42.91 | - | Upgrade |
Operating Expenses | 405.51 | 351.39 | 326.73 | 311.8 | 255.81 | 201.38 | Upgrade |
Operating Income | 65.15 | 97.57 | 87.32 | 70.93 | 89.92 | 51.52 | Upgrade |
Interest Expense | -18.23 | -16.57 | -20.31 | -39.98 | -31.75 | -25.67 | Upgrade |
Interest & Investment Income | 25.99 | 19.69 | 11.44 | 4.54 | 0.9 | 4.63 | Upgrade |
Other Non Operating Income (Expenses) | -10.73 | -0.37 | -0.19 | -1.29 | -0.07 | 1.23 | Upgrade |
EBT Excluding Unusual Items | 62.18 | 100.32 | 78.28 | 34.21 | 59 | 31.71 | Upgrade |
Merger & Restructuring Charges | -13.03 | -9.99 | -3.07 | -11.25 | - | 0.04 | Upgrade |
Impairment of Goodwill | - | -163.24 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | 4.23 | - | - | -10 | -2.6 | 1.62 | Upgrade |
Asset Writedown | -25.87 | - | - | -26.13 | - | - | Upgrade |
Legal Settlements | 16.15 | - | - | - | - | - | Upgrade |
Other Unusual Items | -1.83 | 9.81 | -13.5 | 26.48 | - | -13.28 | Upgrade |
Pretax Income | 41.83 | -63.11 | 61.7 | 13.3 | 56.4 | 20.09 | Upgrade |
Income Tax Expense | 20.39 | 36.45 | 19.75 | -2.61 | 14.42 | -125.43 | Upgrade |
Net Income | 21.44 | -99.56 | 41.96 | 15.91 | 41.98 | 145.52 | Upgrade |
Net Income to Common | 21.44 | -99.56 | 41.96 | 15.91 | 41.98 | 145.52 | Upgrade |
Net Income Growth | - | - | 163.72% | -62.10% | -71.15% | - | Upgrade |
Shares Outstanding (Basic) | 45 | 46 | 46 | 46 | 44 | 43 | Upgrade |
Shares Outstanding (Diluted) | 46 | 46 | 52 | 47 | 46 | 44 | Upgrade |
Shares Change (YoY) | -1.02% | -11.03% | 11.69% | 1.99% | 4.46% | 5.22% | Upgrade |
EPS (Basic) | 0.47 | -2.15 | 0.91 | 0.35 | 0.95 | 3.41 | Upgrade |
EPS (Diluted) | 0.47 | -2.15 | 0.89 | 0.34 | 0.92 | 3.33 | Upgrade |
EPS Growth | - | - | 160.68% | -63.04% | -72.37% | - | Upgrade |
Free Cash Flow | 124.2 | 178.75 | 139.49 | 115.2 | 79.85 | 39.23 | Upgrade |
Free Cash Flow Per Share | 2.71 | 3.87 | 2.68 | 2.48 | 1.75 | 0.90 | Upgrade |
Gross Margin | 65.66% | 64.05% | 61.34% | 57.40% | 63.84% | 58.86% | Upgrade |
Operating Margin | 9.09% | 13.92% | 12.94% | 10.64% | 16.61% | 11.99% | Upgrade |
Profit Margin | 2.99% | -14.20% | 6.22% | 2.39% | 7.75% | 33.87% | Upgrade |
Free Cash Flow Margin | 17.33% | 25.50% | 20.67% | 17.28% | 14.74% | 9.13% | Upgrade |
EBITDA | 150.57 | 176.36 | 162.9 | 151.93 | 118.47 | 71.42 | Upgrade |
EBITDA Margin | 21.01% | 25.16% | 24.13% | 22.78% | 21.88% | 16.62% | Upgrade |
D&A For EBITDA | 85.42 | 78.79 | 75.57 | 81 | 28.55 | 19.91 | Upgrade |
EBIT | 65.15 | 97.57 | 87.32 | 70.93 | 89.92 | 51.52 | Upgrade |
EBIT Margin | 9.09% | 13.92% | 12.94% | 10.64% | 16.61% | 11.99% | Upgrade |
Effective Tax Rate | 48.75% | - | 32.00% | - | 25.57% | - | Upgrade |
Revenue as Reported | 716.79 | 700.97 | 674.98 | 666.82 | 541.53 | 429.65 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.